# Harpoon Therapeutics
 (stock symbol: HARP) Logo in transparent PNG format

## Harpoon Therapeutics
 Logo large

### Harpoon Therapeutics
 Logo large Download PNG (28.89 KB)

![Harpoon Therapeutics
 Logo large Download PNG (28.89 KB)](/img/orig/HARP_BIG-810864f6.png)

## Harpoon Therapeutics
 Logo icon format

### Harpoon Therapeutics
 Logo icon format Download PNG (4.79 KB)

![Harpoon Therapeutics
 Logo icon format Download PNG (4.79 KB)](/img/orig/HARP-d47e0cd8.png)

## About Harpoon Therapeutics


Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

1. Website domain: harpoontx.com
2. Employees: 95
3. Marketcap: $21.91 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
